The costs of developing treatments for Alzheimer's disease: A retrospective exploration

INTRODUCTION: With the exception of the recent accelerated approval of aducanumab, in over 26 years of research and development (R&D) investment in Alzheimer's disease (AD), only five novel drugs—all for symptomatic treatment only—have reached FDA approval. Here, we estimate the costs of AD...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, Jeffrey L., Goldman, Dana P., Simmons‐Stern, Nicholas R., Ponton, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Featured Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940715/
https://www.ncbi.nlm.nih.gov/pubmed/34581499
http://dx.doi.org/10.1002/alz.12450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940715/
https://www.ncbi.nlm.nih.gov/pubmed/34581499
http://dx.doi.org/10.1002/alz.12450

Ejemplares similares